Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
722.42M | 703.24M | 647.51M | 624.81M | 569.54M | 598.57M | Gross Profit |
517.66M | 476.15M | 269.18M | 462.20M | 428.34M | 467.02M | EBIT |
372.25M | 257.03M | 221.52M | 135.57M | 19.04M | 241.22M | EBITDA |
419.10M | 412.61M | 311.81M | 323.35M | 166.21M | 417.96M | Net Income Common Stockholders |
140.76M | 126.71M | 13.76M | -77.61M | -113.26M | 138.42M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
49.31M | 60.47M | 41.28M | 49.31M | 112.00M | 59.08M | Total Assets |
5.75B | 5.30B | 5.39B | 5.75B | 5.97B | 5.99B | Total Debt |
2.70B | 2.44B | 2.45B | 2.70B | 2.39B | 2.37B | Net Debt |
2.65B | 2.38B | 2.41B | 2.65B | 2.28B | 2.31B | Total Liabilities |
2.69B | 2.56B | 2.58B | 2.69B | 2.59B | 2.58B | Stockholders Equity |
3.06B | 2.74B | 2.80B | 3.06B | 3.38B | 3.41B |
Cash Flow | Free Cash Flow | ||||
338.01M | 310.54M | 300.57M | 315.73M | 322.78M | 249.26M | Operating Cash Flow |
338.01M | 310.54M | 300.57M | 315.73M | 356.39M | 354.85M | Investing Cash Flow |
-112.22M | -109.00M | 103.13M | -216.25M | -336.20M | -136.45M | Financing Cash Flow |
-262.57M | -181.56M | -410.30M | -161.71M | 30.14M | -202.11M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $5.52B | 31.39 | 7.02% | 4.65% | 43.27% | 80.97% | |
77 Outperform | $4.26B | 30.30 | 5.15% | 6.59% | 7.81% | 179.16% | |
74 Outperform | $10.71B | 23.21 | 10.53% | 7.24% | 10.56% | 45.37% | |
72 Outperform | $3.26B | 22.17 | 10.56% | 5.08% | 7.44% | 4.23% | |
72 Outperform | $1.61B | 18.08 | 9.39% | 6.50% | 4.46% | 2.24% | |
64 Neutral | $5.68B | ― | -1.93% | 2.82% | 11.30% | ― | |
61 Neutral | $2.84B | 10.78 | 0.41% | 6.09% | 6.01% | -21.16% |
On June 12, 2025, Sabra Healthcare REIT held its annual stockholders meeting where several key decisions were made. The stockholders elected seven directors to the board, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for 2025, and approved the executive compensation plan, reflecting continued confidence in the company’s leadership and strategic direction.
The most recent analyst rating on (SBRA) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Sabra Healthcare REIT stock, see the SBRA Stock Forecast page.
In the first quarter of 2025, Sabra Healthcare REIT reported a net income of $0.17 per diluted share and continued to see growth in its senior housing managed portfolio, with a 16.9% increase in same-store cash NOI. The company exercised its option to acquire additional senior housing assets and was awarded over $200 million in new acquisition opportunities, reflecting its strategic focus on expanding its portfolio. Sabra’s liquidity position remains strong with $1.1 billion available, and Fitch Ratings affirmed its ‘BBB-‘ credit rating with a stable outlook, indicating confidence in its financial stability and growth prospects.